Although a dedicated randomized controlled trial explicitly evaluating the combined impact of SGLT2is and GLP-1 RAs on cardiovascular and renal protection is still needed, the ongoing PRECIDENTD trial (NCT05390892) aiming to clarify these effects in 9000 high-risk individuals with type 2 diabetes, further refined their clinical utility in improving outcomes in this population. The gene discussed is GCG; the disease is type 2 diabetes mellitus.